Novel immunotherapy has revolutionized the landscape of cancer therapy in multiple tumor types since Ipilimumab, the first ICB agent, was approved for the treatment of metastatic melanoma is 2011.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results